PLoS ONE (Jan 2020)

AFP ratio predicts HCC recurrence after liver transplantation.

  • Christine Koch,
  • Theresa Bette,
  • Oliver Waidmann,
  • Natalie Filmann,
  • Christopher Schrecker,
  • Jörg Trojan,
  • Nina Weiler,
  • Johannes Vermehren,
  • Andreas A Schnitzbauer,
  • Wolf Otto Bechstein,
  • Stefan Zeuzem,
  • Eva Herrmann,
  • Martin-Walter Welker

DOI
https://doi.org/10.1371/journal.pone.0235576
Journal volume & issue
Vol. 15, no. 7
p. e0235576

Abstract

Read online

BACKGROUND/AIMS:Hepatocellular carcinoma (HCC) is a leading indication for liver transplantation (LT) worldwide. Early identification of patients at risk for HCC recurrence is of paramount importance since early treatment of recurrent HCC after LT may be associated with increased survival. We evaluated incidence of and predictors for HCC recurrence, with a focus on the course of AFP levels. METHODS:We performed a retrospective, single-center study of 99 HCC patients who underwent LT between January 28th, 1997 and May 11th, 2016. A multi-stage proportional hazards model with three stages was used to evaluate potential predictive markers, both by univariate and multivariable analysis, for influences on 1) recurrence after transplantation, 2) mortality without HCC recurrence, and 3) mortality after recurrence. RESULTS:19/99 HCC patients showed recurrence after LT. Waiting time was not associated with overall HCC recurrence (HR = 1, p = 0.979). Similarly, waiting time did not affect mortality in LT recipients both with (HR = 0.97, p = 0.282) or without (HR = 0.99, p = 0.685) HCC recurrence. Log10-transformed AFP values at the time of LT (HR 1.75, p = 0.023) as well as after LT (HR 2.07, p = 0.037) were significantly associated with recurrence. Median survival in patients with a ratio (AFP at recurrence divided by AFP 3 months before recurrence) of 0.5 was greater than 70 months, as compared to a median of only 8 months in patients with a ratio of 5. CONCLUSION:A rise in AFP levels rather than an absolute threshold could help to identify patients at short-term risk for HCC recurrence post LT, which may allow intensification of the surveillance strategy on an individualized basis.